Product Name :
Bosutinib hydrate
Description:
Bosutinib, also known as SKI-606, is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Bosutinib was approved in 2012
CAS:
918639-08-4
Molecular Weight:
548.46
Formula:
C26H31Cl2N5O4
Chemical Name:
4-[(2, 4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile hydrate
Smiles :
O.CN1CCN(CCCOC2=CC3=NC=C(C#N)C(NC4=CC(OC)=C(Cl)C=C4Cl)=C3C=C2OC)CC1
InChiKey:
BXPOSPOKHGNMEP-UHFFFAOYSA-N
InChi :
InChI=1S/C26H29Cl2N5O3.H2O/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27;/h11-14,16H,4-10H2,1-3H3,(H,30,31);1H2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Fosaprepitant dimeglumine} web|{Fosaprepitant dimeglumine} Neurokinin Receptor|{Fosaprepitant dimeglumine} Biological Activity|{Fosaprepitant dimeglumine} Formula|{Fosaprepitant dimeglumine} manufacturer|{Fosaprepitant dimeglumine} Epigenetic Reader Domain}
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Bosutinib, also known as SKI-606, is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Bosutinib was approved in 2012|Product information|CAS Number: 918639-08-4|Molecular Weight: 548.46|Formula: C26H31Cl2N5O4|Chemical Name: 4-[(2, 4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile hydrate|Smiles: O.{{Paricalcitol} site|{Paricalcitol} VD/VDR|{Paricalcitol} Biological Activity|{Paricalcitol} Formula|{Paricalcitol} custom synthesis|{Paricalcitol} Cancer} CN1CCN(CCCOC2=CC3=NC=C(C#N)C(NC4=CC(OC)=C(Cl)C=C4Cl)=C3C=C2OC)CC1|InChiKey: BXPOSPOKHGNMEP-UHFFFAOYSA-N|InChi: InChI=1S/C26H29Cl2N5O3.PMID:23773119 H2O/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27;/h11-14,16H,4-10H2,1-3H3,(H,30,31);1H2|Technical Data|Appearance: MedKoo Price(USD/100mg): 25|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: To be determined|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|References:|Hall KH, Brooks A, Waller EK. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib. Am J Hematol. 2021 Aug 1;96(8):E293-E295. doi: 10.1002/ajh.26231. Epub 2021 May 25. PMID: 33971041.Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021 Aug 1;96(8):1000-1007. doi: 10.1002/ajh.26238. Epub 2021 May 28. PMID: 33991360.Products are for research use only. Not for human use.|
